Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | PTGFR | P43088 | 3/20 | 0.36 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632019 | 0.82 | CES2 (0.42) | CES2CES1FFAR1FFAR4KMT2A | |
| SCHEMBL23880063 | 0.82 | CES2 (0.35) | CES2CES1KMT2ARIPK1 | |
| SCHEMBL21631905 | 0.81 | PTGFR (0.32) | PTGFRFFAR1FFAR4 | |
| SCHEMBL21708737 | 0.79 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL21632180 | 0.78 | MDM2 (0.38) | PTGFRFFAR1FFAR4KMT2A | |
| SCHEMBL21632072 | 0.77 | FFAR1 (0.44) | PTGFRFFAR1FFAR4KMT2A | |
| SCHEMBL21632237 | 0.76 | CES2 (0.42) | CES2CES1PTGFRGPR17TRPM8 | |
| SCHEMBL1095667 | 0.75 | CES2 (0.39) | CES2CES1TRPM8KMT2ARIPK1 | |
| SCHEMBL21632189 | 0.75 | CCR1 (0.43) | CES2CES1FFAR1FFAR4KMT2A | |
| SCHEMBL24204701 | 0.73 | GPR17 (0.37) | PTGFRGPR17FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | CES2 133/4885CES1 155/4885PTGFR 1050/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | CES2 133/4885CES1 155/4885PTGFR 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.